384 related articles for article (PubMed ID: 25804234)
1. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes.
Chekhun SV; Zadvorny TV; Tymovska YO; Anikusko MF; Novak OE; Polishchuk LZ
Exp Oncol; 2015 Mar; 37(1):58-63. PubMed ID: 25804234
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
3. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
Gudadze M; Kankava K; Mariamidze A; Mosidze T; Burkadze G
Georgian Med News; 2013 Sep; (222):50-7. PubMed ID: 24099815
[TBL] [Abstract][Full Text] [Related]
4. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
Gudadze M; Kankava Q; Mariamidze A; Burkadze G
Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer.
Tsang JY; Huang YH; Luo MH; Ni YB; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
Breast Cancer Res Treat; 2012 Nov; 136(2):407-17. PubMed ID: 23053657
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
Liu C; Luo Y; Liu X; Lu P; Zhao Z
Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
9. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
11. The distribution of CD44+/CD24- cancer stem cells in breast cancer and its relationship with prognostic factors.
Cabuk D; Yetimoglu E; Simsek T; Gacar G; Subasi C; Canturk Z; Ercin C; Karaoz E; Uygun K
J BUON; 2016; 21(5):1121-1128. PubMed ID: 27837613
[TBL] [Abstract][Full Text] [Related]
12. Association of CD44
Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
[TBL] [Abstract][Full Text] [Related]
13. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
14. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
[TBL] [Abstract][Full Text] [Related]
15. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
Tsunoda Y; Sakamoto M; Sawada T; Sasaki A; Yamamoto G; Tachikawa T
Oncology; 2011; 81(5-6):336-44. PubMed ID: 22237177
[TBL] [Abstract][Full Text] [Related]
16. Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors.
Uchôa Dde M; Graudenz MS; Callegari-Jacques SM; Hartmann CR; Ferreira BP; Fitarelli-Kiehl M; Edelweiss MI
Pathol Res Pract; 2014 Jul; 210(7):432-9. PubMed ID: 24726267
[TBL] [Abstract][Full Text] [Related]
17. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
Lü X; Xu K; Lü H; Yin Y; Ma C; Liu Y; Li H; Suo Z
Ultrastruct Pathol; 2011 Apr; 35(2):72-8. PubMed ID: 21299347
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
19. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.
Nogi H; Suzuki M; Kamio M; Kato K; Kawase K; Toriumi Y; Takeyama H; Fukushima H; Morikawa T; Uchida K
Oncol Rep; 2011 Apr; 25(4):1109-15. PubMed ID: 21308353
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]